THE LATEST FROM RAKOVINA
Discovery in motion.
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
download VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for...
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
DOWNLOAD AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V:...
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
Accepted Abstracts Highlight Advances in AI-Driven Oncology Pipeline DOWNLOAD VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through...
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
DOWNLOAD VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that the TSXV has...
Rakovina Therapeutics Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
DOWNLOAD VANCOUVER, British Columbia, March 5, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce closing of its...
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
DOWNLOAD Proposed $1.0 Million Convertible Debenture and Warrant Financing andConcurrent Common Share Private Placement Up to $1.0 MillionIntended to Support Near-Term Operations Vancouver, British Columbia – February 20, 2026 – Rakovina Therapeutics Inc. (TSX-V:...
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
DOWNLOAD Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field. Expanded Opportunity:...
Rakovina Therapeutics Announces Corporate Update Including up to $1.6 Million in New Financing, Leadership Appointments and Debt Restructuring
Proposed $1.0 million Convertible Debenture and concurrent $600,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets ExecutionCurrent Convertible Debenture Maturity Extended; Further...
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
DOWNLOAD Vancouver, British Columbia, January 8, 2026 - Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery and Variational AI, a leader in generative...
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
DOWNLOAD Vancouver, British Columbia, December 17, 2025 - Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that...
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies Vancouver, British Columbia, December 10, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a...
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, December 1, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer...
